Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
About 60% of patients with breast cancer who are classed as ‘negative’ for human epidermal growth factor receptor 2 (HER2) may still express it at low levels — although traditional HER2-targeting therapies are not effective in such cases. These ‘HER2-low’ patients are initially treated according to their hormone receptor status, but after relapse they have very limited treatment options.